Dr. Gergis's research interests are multifaceted. He has contributed to studies examining healthcare costs among patients with hematologic malignancies undergoing allogeneic transplants, highlighting the financial implications of extended hospital stays and readmissions . Additionally, he has explored the efficacy of the two-step allogeneic stem cell transplantation approach in patients with lymphoid malignancies, demonstrating rapid engraftment and excellent outcomes . His work also includes investigating vaccination responses following autologous stem cell transplantation and evaluating survival rates in myelofibrosis patients undergoing the two-step HSCT approach.
He specializes in treating high-risk myeloid malignancies, graft-versus-host disease (GVHD), and hematopoietic stem cell transplantation (HSCT) for patients lacking matched donors. His clinical expertise encompasses both allogeneic and autologous stem cell transplants, as well as immunotherapy approaches for hematologic cancers.